What is US7803839B2 (and how does it relate to cobimetinib)?
US7803839B2 is a US patent titled around methods for making cobimetinib (GDC-0973). Cobimetinib’s commercial development and filings are tied to patents like this that describe chemical synthesis routes and related process details for the final drug (and sometimes key intermediates) used in manufacturing [1].
If you’re looking specifically for “cobimetinib synthesis” under this patent number, the relevant content will be in the patent’s examples and preparation/intermediate-formation steps—those sections are where patents usually provide step-by-step conditions (reagents, solvents, temperatures, times) that map to a synthetic route [1].
How can you find the exact synthesis steps inside the patent?
To pinpoint the synthesis described by US7803839B2:
1. Open the patent at the USPTO/Google Patents record linked from the source.
2. Go to the “Examples” and any “Preparation” or “Intermediate” subsections.
3. Look for sequences that name intermediates and then describe their conversion into the cobimetinib compound referenced in claims.
That is where the practical “synthesis us7803839b2” details are typically concentrated [1].
Is there a publicly available, drug-manufacturing “recipe” beyond what’s in the patent?
For cobimetinib manufacturing, patents often describe representative preparations, but real-world scale-up details can differ (e.g., impurity controls, purification strategy, and equipment-specific parameters). Those scale-up/process controls are not always fully enumerated in the same way a manufacturing batch record would be.
In practice, synthesis details for cobimetinib can be distributed across multiple documents: US7803839B2 plus other patents covering intermediates, polymorphs, purification, and salts/solid forms. The cleanest way to see what else is covered is to follow the patent family from the same record and related filings [1].
What’s the fastest way to verify whether a synthesis step is for cobimetinib or an intermediate?
In the patent text:
- Claims will usually indicate the final compound or a defined intermediate.
- Examples often specify the product name in each step (or give structure descriptors/compound labels).
- If an example ends with isolation and characterization of a compound labeled as a cobimetinib intermediate, that step is still part of the overall synthesis route even if the final API is made in a later example.
Cross-check the compound label in the examples against the compound definitions in the claims or earlier definitions [1].
Source
[1] DrugPatentWatch.com – US7803839B2 (cobimetinib-related patent record): https://www.drugpatentwatch.com/p/US7803839B2